Cure My Disease

Don't miss your cure!

 Log in / Sign up

Math model may Fine-Tune radiation for throat cancer patients

NCT ID NCT03656133

Knowledge-focused Sponsor: H. Lee Moffitt Cancer Center and Research Institute Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tested whether a mathematical model could help doctors choose the best radiation schedule for people with HPV-positive throat cancer. The goal was to see if personalized dosing could shrink tumors faster than standard treatment. Fifty-five adults took part, and researchers measured tumor shrinkage after four weeks and complete response after two to three months.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

55 people

The number who actually took part.

Started

Sep 2018

Finished

Mar 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Stated willingness to comply with all study procedures and availability for the duration of the study * Male or female, aged ≥ 18 years * Pathologically (histologically or cytologically) proven diagnosis of p16+ or HPV+ squamous cell carcinoma (including the histological variants papillary squamous cell carcinoma and basaloid squamous cell carcinoma) of the oropharynx; cytologic diagnosis from a cervical lymph node is sufficient in the presence of clinical evidence of a primary tumor in the oropharynx. Clinical evidence should be documented, and may consist of pathology, palpation, imaging, or endoscopic evaluation, and should be sufficient to estimate the size of the primary (for T stage). * American Joint Committee on Cancer (AJCC) 8th edition staging T1-3 N0-1 MO * Patients must have clinically or radiographically evident measurable disease at the primary site or at nodal stations. * CT or MRI performed at least 1 week apart. This can consist of diagnostic imaging and radiation therapy planning imaging. * No evidence of distant metastases * Eastern Cooperative Oncology Group Performance Status 0 to 3 Exclusion Criteria: * Age \< 18 * Positive urine pregnancy test * Evidence of distant metastases * Gross total excision of both primary and nodal disease; this includes tonsillectomy, local excision of primary site, and nodal excision that remove all clinically and radiographically evident disease * Prior radiotherapy to the region of the study cancer that would result in overlap of radiation therapy fields * Patients with a medical condition or social situation that at the discretion of the PI would preclude them from completion of the trial

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HPV positive oropharyngeal squamous cell carcinoma are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

human papillomavirus-related squamous cell carcinoma laryngeal disorder oropharyngeal carcinoma oropharynx cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Oropharyngeal cancer

Contacts and locations

Locations

  • H Lee Moffitt Cancer Center and Research Institute

    Tampa, Florida, 33612, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.